Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Aurélien Marabelle, Holbrook E K Kohrt, Idit Sagiv-Barfi et al. · Journal of Clinical Investigation · 2013
Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti-CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.
Cited by 307 works. doi:10.1172/jci73340 Open-access PDF
Authors
- Aurélien Marabelle
- Holbrook E K Kohrt
- Idit Sagiv-Barfi
- Bahareh Ajami
- Robert C. Axtell
- Gang Zhou
- Ranjani Rajapaksa
- James Anthony Torchia
- Joshua Brody
- Richard H. Luong
- Michael D. Rosenblum
- Lawrence Steinman
- Hyam I. Levitsky
- Victor Tse
- Ronald Levy
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- The blockade of immune checkpoints in cancer immunotherapy
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse
- The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3
- Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
- Cancer immunotherapy comes of age
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study